A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm
详细信息 查看全文
- 作者：Michele Ceribelli1 ; 7 ; Zhiying Esther Hou2 ; Priscilla N. Kelly1 ; Da Wei Huang1 ; George Wright3 ; Karthik Ganapathi4 ; 11 ; Moses O. Evbuomwan4 ; Stefania Pittaluga4 ; Arthur L. Shaffer1 ; Guido Marcucci5 ; Stephen J. Forman5 ; Wenming Xiao6 ; Rajarshi Guha7 ; Xiaohu Zhang7 ; Marc Ferrer7 ; Laurence Chaperot8 ; 9 ; Joel Plumas8 ; 9 ; Elaine S. Jaffe4 ; Craig J. Thomas7 ; Boris Reizis2 ; 10 ; boris.reizis@nyumc.org" class="auth_mail" title="E-mail the corresponding author ; Louis M. Staudt1 ; 12 ; lstaudt@mail.nih.gov" class="auth_mail" title="E-mail the corresponding author
- 关键词：BPDCN ; TCF4 ; BRD4 ; HTS ; super-enhancer
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：14 November 2016
- 年：2016
- 卷：30
- 期：5
- 页码：764-778
- 全文大小：4934 K
文摘
- •
The E-box transcription factor TCF4 is a lineage-survival oncogene in BPDCN
- •
BET inhibitors are highly toxic to BPDCNs, both in vitro and in vivo
- •
A druggable TCF4/BRD4 transcriptional network sustains malignancy in BPDCN
- •
BET inhibitors should be explored for the clinical management of BPDCN